UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
172.99 +1.31 (+0.76%) 04/17/25 [NYSE]
173.00 x 300 174.20 x 100
Realtime by (Cboe BZX)
173.00 x 300 174.20 x 100
Realtime 174.20 +1.21 (+0.70%) 04/17/25
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
171.91
Day High
175.20
Open 172.57
Previous Close 171.68 171.68
Volume 8,998,000 8,998,000
Avg Vol 10,122,955 10,122,955
Stochastic %K 19.75% 19.75%
Weighted Alpha -2.22 -2.22
5-Day Change -1.21 (-0.69%) -1.21 (-0.69%)
52-Week Range 153.58 - 218.66 153.58 - 218.66
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 306,015,520
  • Shares Outstanding, K 1,768,978
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 9,130 M
  • EBITDA $ 17,516 M
  • 60-Month Beta 0.55
  • Price/Sales 5.39
  • Price/Cash Flow 11.50
  • Price/Book 90.18

Options Overview Details

View History
  • Implied Volatility 34.23% ( -1.55%)
  • Historical Volatility 35.24%
  • IV Percentile 96%
  • IV Rank 51.19%
  • IV High 51.27% on 04/08/25
  • IV Low 16.36% on 05/10/24
  • Put/Call Vol Ratio 0.69
  • Today's Volume 13,764
  • Volume Avg (30-Day) 33,220
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 425,330
  • Open Int (30-Day) 392,966

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.38
  • Number of Estimates 3
  • High Estimate 2.39
  • Low Estimate 2.36
  • Prior Year 2.31
  • Growth Rate Est. (year over year) +3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
164.39 +5.23%
on 04/09/25
Period Open: 214.47
215.18 -19.61%
on 03/18/25
-41.48 (-19.34%)
since 03/17/25
3-Month
164.39 +5.23%
on 04/09/25
Period Open: 171.56
218.66 -20.89%
on 03/10/25
+1.43 (+0.83%)
since 01/17/25
52-Week
153.58 +12.64%
on 05/30/24
Period Open: 164.25
218.66 -20.89%
on 03/10/25
+8.74 (+5.32%)
since 04/17/24

Most Recent Stories

More News
Is AbbVie Stock a Buy?

The pharmaceutical giant has been a roller coaster over the past several months.

AGN.AX : 0.680 (unch)
ABBV : 172.99 (+0.76%)
Housing Figures in Picture for Next Week

U.S. Monday Economic Lookahead U.S. leading economic indicators (March) Featured Earnings ...

MEDP : 296.28 (-0.07%)
AON : 367.41 (-1.45%)
GOOGL : 151.16 (-1.42%)
AGNC : 8.34 (+0.48%)
WRB : 68.80 (+0.51%)
HCA : 335.01 (+1.21%)
NVS : 110.86 (+1.17%)
ABBV : 172.99 (+0.76%)
TMUS : 262.04 (+0.92%)
TSLA : 241.37 (-0.07%)
T : 27.15 (+0.48%)
IBM : 238.81 (+0.10%)
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

SRPT : 53.79 (-0.28%)
BMRN : 59.17 (+0.60%)
ABBV : 172.99 (+0.76%)
MRNA : 24.72 (-1.89%)
AMGN : 277.29 (-1.89%)
Top Research Reports for AbbVie, TJX & Charles Schwab

Tuesday, April 15, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV),...

TJX : 127.62 (+1.04%)
ENB : 45.37 (+1.79%)
SCHW : 76.15 (+0.59%)
ABBV : 172.99 (+0.76%)
HSBC : 52.50 (+1.00%)
GE : 181.79 (-0.36%)
The Zacks Analyst Blog Merck and AbbVie

For Immediate ReleasesChicago, IL – April 15, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

MRK : 78.00 (+2.01%)
ABBV : 172.99 (+0.76%)
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?

Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While AbbVie also markets products for aesthetics, neuroscience and eye care, Merck has...

NVO : 58.08 (-7.63%)
MRK : 78.00 (+2.01%)
LLY : 839.96 (+14.30%)
ABBV : 172.99 (+0.76%)
Earnings Preview: What to Expect From AbbVie's Report

AbbVie is scheduled to report its first-quarter results this month, with analysts anticipating a modest growth in earnings.

XLV : 135.49 (-0.59%)
$SPX : 5,282.70 (unch)
ABBV : 172.99 (+0.76%)
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis

For Immediate ReleasesChicago, IL – April 14, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

AZN : 67.59 (+0.81%)
NVS : 110.86 (+1.17%)
ABBV : 172.99 (+0.76%)
Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More

This week, the European Commission granted marketing authorization to the expanded use of AbbVie’s ABBV Rinvoq and AstraZeneca’s AZN blockbuster cancer drugs, Imfinzi and Daiichi-Sankyo partnered,...

AZN : 67.59 (+0.81%)
NVS : 110.86 (+1.17%)
ABBV : 172.99 (+0.76%)
Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?

Pfizer’s PFE stock hit a new 52-week low of $20.92 on Wednesday but recovered thereafter and closed at $22.49Though the stock has seen ups and downs in the past year, the latest price decline is largely...

LLY : 839.96 (+14.30%)
ABBV : 172.99 (+0.76%)
PFE : 22.14 (+0.45%)
BNTX : 98.76 (+0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 178.12
2nd Resistance Point 176.66
1st Resistance Point 174.82
Last Price 172.99
1st Support Level 171.53
2nd Support Level 170.07
3rd Support Level 168.24

See More

52-Week High 218.66
Fibonacci 61.8% 193.80
Fibonacci 50% 186.12
Fibonacci 38.2% 178.44
Last Price 172.99
52-Week Low 153.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro